Tian et al. [212] investigated luteolin (LUT), a natural flavonoid, as a dietary supplement alternative to DMF in a CPZ‐induced demyelination mouse model. LUT treatment significantly restored motor coordination and spatial memory, with efficacy comparable to that of DMF. It promoted MBP expression, mitigated oxidative damage by regulating the levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH‐Px), and malondialdehyde (MDA), and preserved myelin integrity. Furthermore, LUT significantly promoted Nrf2 nuclear translocation and upregulated the expression of heme oxygenase‐1 (HO‐1) and NAD(P)H quinone dehydrogenase 1 (NQO1). Molecular docking analyses revealed that LUT exhibits stronger binding affinity to the target protein Keap1 (Kelch‐like ECH‐associated protein 1) and lower potential off‐target toxicity compared to the major active metabolite of DMF. In conclusion, LUT exerts significant neuroprotective effects by activating the Nrf2 pathway, with efficacy comparable to DMF but superior safety profiles. These findings highlight LUT as a promising natural compound bridging functional foods and MS therapy, laying the foundation for the development of LUT‐rich dietary regimens as adjuvant treatments for MS.
Matrine, a tetracyclic quinazoline alkaloid, is found in the seeds and roots of Sophora flavescens Alt. Matrine at a dose of 150–200 mg/kg significantly inhibits the secretion of inflammatory cytokines by Th1/Th17 cells in EAE mice, upregulates the expression of neurotrophic factor NT3, and thereby prevents inflammation and demyelination in EAE mice. It also inhibits the necrosis of CNS oligodendrocytes and improves the neurological function score in EAE mice [152, 153]. Matrine regulates the polarization of microglia from M1 to M2 phenotype and repairs p75 neurotrophic factor receptor (p75NTR) and neurotrophic factor precursor (proNGF) by inhibiting the release of interleukin‐33 (IL‐33) and soluble ST2 (sST2) in the brain tissue of EAE mice, exerting its therapeutic effects [154, 155]. Matrine reduces demyelination in EAE rats, inhibits extravasation of Evans blue (EB) through the BBB, dose‐dependently increases the mRNA expression of collagen IV and tight junction protein‐1 (ZO‐1), and downregulates matrix metalloproteinase‐9 (MMP‐9)/MMP‐2 while upregulating tissue inhibitors of metalloproteinase‐1 (TIMP‐1)/TIMP‐2. Matrine at a dose of 250 mg/kg induced a significantly greater increase in TIMP‐1 expression compared to dexamethasone, resulting in a significant improvement in clinical symptoms in EAE rats [156]. A recent seminal study [157] demonstrated that combined oxymatrine treatment significantly reduced neurological deficit scores, ameliorated immune cell infiltration and demyelination, and concomitantly rectified stroke‐induced gut dysbiosis in MS. Specifically, this intervention notably diminished the species richness and abundance of intestinal pathogenic and opportunistic pathogens, while increasing those of probiotic genera (e.g., Bifidobacterium and Lactobacillus). It also modulated the concentrations of various short‐chain fatty acids (SCFAs), suppressed inflammatory responses in both intestinal and brain tissues, markedly upregulated the mRNA expression of tight junction proteins (ZO‐1 and Occludin) in the gut–brain axis, and substantially enhanced intestinal barrier and BBB integrity—ultimately exerting a therapeutic effect on MS via the gut–brain axis regulatory pathway. Furthermore, fecal microbiota transplantation (FMT) from oxymatrine‐treated experimental autoimmune EAE mice alleviated clinical severity and weight loss in recipient mice, mitigated inflammatory infiltration and demyelination in spinal cord tissues, reduced the frequencies of Th2 and Th17 cells in the spleen and lymph nodes, increased Treg cell populations, decreased peripheral blood IL‐17A levels, and elevated IL‐10 concentrations. These findings further corroborate oxymatrine’s pivotal role in regulating the intestinal microenvironment of MS, providing critical preclinical evidence for its potential as a gut‐targeted therapeutic agent in MS management [157].
Rhubarb contains mainly anthraquinone compounds, including free anthraquinones such as rhein, aloe‐emodin, emodin, physcion, chrysophanol, and anthraquinone glycosides such as emodin‐8‐O‐glucoside. Emodin, a natural product derived from rhubarb and other herbal plants, exhibits various activities such as anti‐inflammatory and antioxidant effects. Current studies have found that emodin possesses neuroprotective effects in CNS diseases. It has been found that emodin can improve clinical symptoms, inhibit inflammatory cell infiltration and demyelination in the spinal cord, and suppress inflammatory cell infiltration in the brain, thereby reducing inflammation and exerting neuroprotective effects in the EAE rat model. Emodin can also inhibit the inflammatory levels in models of microglial inflammation. In the EAE rat model and microglial inflammation model, emodin can suppress NLRP3 inflammasome activation and pyroptosis. Emodin regulates NLRP3 inflammasome activation and pyroptosis through the SIRT1/PGC‐1α pathway [216]. Yang et al. [217] investigated the therapeutic potential of 2‐bromo‐1,4‐naphthalenedione (BrQ), a naphthalenedione derivative, in EAE—an animal model of MS—and elucidated its underlying mechanisms. Notably, BrQ‐treated mice exhibited alleviated EAE symptoms, including reduced clinical scores, diminished leukocyte infiltration, and attenuated demyelination in the CNS. Furthermore, the study indicated that BrQ does not directly affect the remyelination process. Through CellChat analysis based on bulk RNA‐seq data, combined with flow cytometric validation, the researchers found that BrQ significantly promoted the expansion of CD8+ T cells in the peripheral immune system of EAE mice and enhanced their crosstalk with other immune cell subsets. Subsequent CD8+ T cell depletion experiments confirmed that BrQ alleviates EAE in a CD8+ T cell‐dependent manner. Mechanistically, the expanded CD8+ T cells were found to selectively reduce antigen‐specific CD4+ T cells, thereby inhibiting the development of Th1 and Th17 cells in vivo and ultimately mitigating EAE. Collectively, these findings highlight the critical role of BrQ in regulating MS pathogenesis, suggesting its potential as a novel drug candidate for the treatment of MS and other autoimmune diseases [217].